EyePoint Pharmaceuticals, Inc.
EYPT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $1 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $1 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -6% | 11.1% | 12.1% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 91.4% | 89.9% | 79.9% | 77.9% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -298.6% | -149.9% | -233.4% | -135.8% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -302.4% | -153.8% | -247% | -158.1% |
| EPS Diluted | -2.32 | -1.82 | -2.74 | -2.03 |
| % Growth | -27.5% | 33.6% | -35% | – |
| Operating Cash Flow | -$0 | $0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |